Olema Pharmaceuticals, Inc.
OLMA$243M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSAN FRANCISCO122 employees
Drugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
This month
Market Overview
Stock performance and key metrics
OLMA News
Catalyst Timeline
2 upcoming, 1 past
Phase 3Next
Palazestrant Phase 3 Est. Readout
June 2026~ConfirmedPalazestrant510
Primary completion for Palazestrant trial (NCT06016738) in Breast Cancer
Source1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Drug Pipeline
Palazestrant
Breast Cancer
Ribociclib
Breast Cancer
OP-1250
Hormone Receptor Positive Breast Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Palazestrant | Phase 3 | Breast Cancer | - | - |
Ribociclib | Phase 3 | Breast Cancer | - | - |
OP-1250 | Phase 2 | Hormone Receptor Positive Breast Carcinoma | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply